Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edmund Pasimio

Physical Medicine & Rehabilitation Las Vegas, NV Medical Doctor

NPI 1114015229 CMS profile 187009

601 S Rancho Dr, Suite #A-6, Las Vegas, NV 89106

Open in the dashboard

General payments

$6,433

313 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edmund Pasimio of Las Vegas, NV is reported in the CMS Open Payments database as having received $6,433 across 313 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $377 18
2024 General $1,108 34
2023 General $835 42
2022 General $731 40
2021 General $1,093 53
2020 General $867 26
2019 General $1,422 100

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edmund Pasimio
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Edmund Pasimio were reported at $377. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Edmund Pasimio Physical Medicine & Rehabilitation median Middle half National median
2019 $1,422 $133 $45–$390 $163
2020 $867 $88 $29–$272 $114
2021 $1,093 $116 $33–$360 $132
2022 $731 $123 $40–$378 $149
2023 $835 $131 $43–$396 $160
2024 $1,108 $141 $45–$409 $164
2025 $377 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Forte Bio-Pharma LLC $936 15 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $915 49 payments
  3. Collegium Pharmaceutical, Inc. $843 49 payments
  4. AbbVie, Inc. $584 28 payments
  5. Scilex Pharmaceuticals Inc. $420 28 payments
  6. Amgen Inc. $369 16 payments
  7. AstraZeneca Pharmaceuticals LP $245 2 payments
  8. Zyla Life Sciences $216 33 payments
  9. Daiichi Sankyo Inc. $213 16 payments
  10. Janssen Pharmaceuticals, Inc $150 1 payment
  11. Other $1,543 76 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,433 313 payments
Products named General payments · program years 2019–2025
  1. RELISTOR $851 45 payments
  2. XTAMPZA $659 39 payments
  3. PROLATE Pain $520 2 payments
  4. NALOCET Pain $468 1 payment
  5. Prolate Pain $468 1 payment
  6. PROLATE Pain $468 1 payment
  7. NALOCET Pain $416 13 payments
  8. AIMOVIG $398 19 payments
  9. QULIPTA $352 17 payments
  10. ZTLido $310 20 payments
  11. Other $4,913 246 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 60 drugs

Part D claims

3,973

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$203,969

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

25.3%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 243 $49,497
Xtampza Er Oxycodone Myristate Brand 81 $42,875
Relistor Methylnaltrexone Bromide Brand 13 $40,962
Oxycodone Hcl Generic 542 $12,998
Naloxone Hcl Generic 116 $8,608
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 230 $7,366
Linzess Linaclotide Brand 12 $6,421
Movantik Naloxegol Oxalate Brand 18 $6,019
Morphine Sulfate Er Morphine Sulfate Brand 320 $5,609
Diclofenac Sodium Generic 22 $4,537

The 10 drugs with the highest cost, of 60 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$122,025

Of which drugs: $412

Medicare patients

194

Average age 64

Services billed

4,073

123 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 65%
Diabetes 40%
Depression 32%
COPD 27%
Ischemic heart disease 23%
Chronic kidney disease 21%
Heart failure 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 18 2,080 $215
Injection, methylprednisolone acetate, 80 mg J1040 Office 11 12 $92
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 52 84 $80
Injection, ketorolac tromethamine, per 15 mg J1885 Office 42 59 $25
Injection, bupivicaine, not otherwise specified, 0.5 mg J0665 Office 18 27 $0

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $150
$150 — —
QULIPTA
  • AbbVie, Inc. $110
$110 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $102
$102 81 —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $72
$72 13 —
PROLATE
  • Forte Bio-Pharma LLC $68
$68 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

313 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record